本帖最后由 老马 于 2012-1-13 21:20 编辑 7 B8 `0 a) l7 O% G8 q
# F5 r3 g- c) ~$ t! d
爱必妥和阿瓦斯丁的比较
2 F0 S8 H6 R M/ E' Q+ |- D
& ^5 J0 d/ V t- V: l
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
: L( z2 Y3 ^; ?# g( l
: k6 d& r6 r, `9 L8 d9 g& ]0 v/ y. v
" M! k1 `* P! x8 h6 }; `* Y) j# ohttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial// T; R5 B0 h; J b- `: Y+ N o
==================================================
, I3 t( {$ P8 q9 jOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)8 G$ d; ~# Q$ a- w7 m! s' G
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
4 R! O2 A% H' H4 eResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
6 C4 F8 t7 e t( Q
|